The overexpression of CD105 with the co-expression of CD44 and CD106 was determined in paclitaxel-resistant ovarian cancer cell lines and primary ovarian cancer cells resistant to different chemotherapeutics. This evidence concerns the gene CD44 and ovarian carcinoma.